Cite
Hartung HP, Derfuss T, Cree BA, et al. Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. Mult Scler. 2021;13524585211024997doi: 10.1177/13524585211024997.
Hartung, H. P., Derfuss, T., Cree, B. A., Sormani, M. P., Selmaj, K., Stutters, J., Prados, F., MacManus, D., Schneble, H. M., Lambert, E., Porchet, H., Glanzman, R., Warne, D., Curtin, F., Kornmann, G., Buffet, B., Kremer, D., Küry, P., Leppert, D., Rückle, T., & Barkhof, F. (2021). Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. Multiple sclerosis (Houndmills, Basingstoke, England), 13524585211024997. https://doi.org/10.1177/13524585211024997
Hartung, Hans-Peter, et al. "Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study." Multiple sclerosis (Houndmills, Basingstoke, England) vol. (2021): 13524585211024997. doi: https://doi.org/10.1177/13524585211024997
Hartung HP, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, Prados F, MacManus D, Schneble HM, Lambert E, Porchet H, Glanzman R, Warne D, Curtin F, Kornmann G, Buffet B, Kremer D, Küry P, Leppert D, Rückle T, Barkhof F. Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. Mult Scler. 2021 Jul 09;13524585211024997. doi: 10.1177/13524585211024997. Epub 2021 Jul 09. PMID: 34240656.
Copy
Download .nbib